2 terminated, 2 unknown, 1 completed. 2 Not applicable, 2 Phase 3, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Unknown 2 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow BT-001: new trials by email Literature Review of BT-001 trials Research Report on BT-001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Cognitive Behavioral Digital Therapeutic InterventiON for Glycemic Control in Type 2 Diabetes Mellitus BT-001, Control Mobile Application - Diabetes Type 2 | Not applicable | Unknown | Better Therapeutics | 500 | 2022-03-07 | 2023-10-30 |
| Digital Therapeutic Based Investigation to Improve Glycemic Control in Patients With Type 2 Diabetes and Residual Hyperglycemia on Stable Medical Therapy BT-001, Control App - Diabetes Mellitus, Type 2 | Not applicable | Unknown | Better Therapeutics | 500 | 2022-02-14 | 2023-10-30 |
| Use of an Investigational Digital Therapeutic in Patients With Type 2 Diabetes BT-001 - Type2 Diabetes | Phase 3 | Terminated | Better Therapeutics | 76 | 2021-10-04 | 2023-09-28 |
| Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes BT-001, Physician-guided Standard of Care for type 2 diabetes - Type 2 Diabetes | Phase 3 | Completed | Better Therapeutics | 668 | 2021-04-22 | 2023-09-28 |
| A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors BT-001, Pembrolizumab [KEYTRUDA®] - Metastatic Cancer, Soft Tissue Sarcoma | Phase 1 / Phase 2 | Terminated | Transgene | 31 | 2021-02-25 | 2025-11-21 |
Diabetes Mellitus, Type 2 (3) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Melanoma (1) · Neoplasm Metastasis (1) · Sarcoma (1) · Triple Negative Breast Neoplasms (1) · Vaccinia (1)
Better Therapeutics (4) · Transgene (1)
United States (4) · Belgium (1) · France (1)
Mark Berman, MD (1)